FDA Releases Guidance for Industry on Safety Data Collection in Late-Stage Clinical Investigations

Summary

The US Food and Drug Administration (FDA) has published a guidance document to help pharmaceutical companies determine the necessary safety data to collect in late-stage clinical trials for new drugs, aiming to streamline the process and reduce costs.